MedTrace Logo

Post-market Evaluation of HEMOBLAST™ Bellows in Spine Surgery

NCT04471350 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2021-08-30

No results posted yet for this study

Summary

Prospective, multi-center, multi-national post-market study evaluating the performance and safety HEMOBLAST™ Bellows in spine surgery

Conditions

  • Hemostasis

Interventions

DEVICE

HEMOBLAST™ Bellows

Surgeon has chosen to use HEMOBLAST™ Bellows as an adjunct to hemostasis when control of minimal, mild, or moderate bleeding by conventional procedures is ineffective or impractical in spine surgery.

Sponsors & Collaborators

  • Biom'Up France SAS

    lead INDUSTRY

Principal Investigators

  • Pierre-Marie Longis, MD · L'Hôpital privé du Confluent

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-30
Primary Completion
2022-06-30
Completion
2022-08-31
FDA Device
Yes

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04471350 on ClinicalTrials.gov